Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October

Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report) was the recipient of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 528,200 shares, a decline of 18.1% from the October 15th total of 644,700 shares. Based on an average daily trading volume, of 159,300 shares, the short-interest ratio is currently 3.3 days. Approximately 2.1% of the company's shares are sold short.

Wall Street Analyst Weigh In

Separately, William Blair upgraded shares of Vistagen Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th.

Institutional Trading of Vistagen Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. American Century Companies Inc. raised its holdings in shares of Vistagen Therapeutics by 49.1% in the 2nd quarter. American Century Companies Inc. now owns 30,315 shares of the company's stock worth $105,000 after purchasing an additional 9,984 shares during the period. Jane Street Group LLC purchased a new stake in Vistagen Therapeutics in the third quarter worth $59,000. Blair William & Co. IL raised its stake in shares of Vistagen Therapeutics by 29.2% in the second quarter. Blair William & Co. IL now owns 88,466 shares of the company's stock valued at $308,000 after buying an additional 20,000 shares during the period. HighTower Advisors LLC purchased a new position in shares of Vistagen Therapeutics during the 3rd quarter valued at $64,000. Finally, Acadian Asset Management LLC bought a new position in shares of Vistagen Therapeutics during the 1st quarter worth $169,000. Hedge funds and other institutional investors own 78.39% of the company's stock.

Vistagen Therapeutics Price Performance

Shares of NASDAQ:VTGN traded down $0.10 during midday trading on Friday, hitting $2.63. 355,784 shares of the company's stock were exchanged, compared to its average volume of 194,282. The company has a market cap of $73.22 million, a PE ratio of -2.10 and a beta of 0.78. Vistagen Therapeutics has a 12 month low of $2.58 and a 12 month high of $5.86. The stock has a 50 day moving average price of $3.05 and a 200-day moving average price of $3.51.

Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.06. Vistagen Therapeutics had a negative return on equity of 36.35% and a negative net margin of 4,521.71%. The company had revenue of $0.08 million for the quarter, compared to analysts' expectations of $0.30 million. During the same quarter in the previous year, the firm earned ($0.94) earnings per share. On average, analysts anticipate that Vistagen Therapeutics will post -1.85 EPS for the current fiscal year.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.